Trigger-Point Bupivacaine Injection Causing A “Heart-Break”

Muhammad Osama,Venkata Satish Pendela,Mohamed Mohamed,Vishal Parikh

DOI: https://doi.org/10.1016/j.cardfail.2023.10.378

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Bupivacaine is a long-acting amide local anesthetic that is frequently used for neuraxial analgesia and anesthesia, peripheral nerve blocks, and subcutaneous and tissue infiltration. Adverse cardiac events like arrhythmias and cardiac arrest are fatal complications of bupivacaine systemic absorption. We present a case of non-ST segment elevation myocardial infarction and acute left ventricular dysfunction with local injection of bupivacaine. Case A 59-year-old woman received trigger point injections into bilateral greater occipital nerves and trapezius trigger points as a part of the treatment cycle for her bilateral occipital neuralgia, myofascial pain syndrome at a pain clinic. Within ten minutes she started feeling shortness of breath and chest tightness and hence presented to the emergency department (ED). She has been receiving trigger point injections for several years (once every 6 weeks) but this is the first time with Bupivacaine. Upon arrival at the ED, she was found to be hypoxic and in acute respiratory distress. Initial ECG showed marginal ST segment depressions in the inferolateral leads (Fig 1A) and she had significant troponin elevation. Chest X-ray was suggestive of pulmonary edema. A trans-thoracic echocardiogram(TTE) revealed global hypokinesis with moderate left ventricular dysfunction (Ejection fraction EF 35-40%). She underwent a coronary angiogram which showed normal coronary arteries. Her symptoms improved with diuresis. She was discharged home on Guideline-directed medical therapy (GDMT). At 10 days follow-up, her left ventricular systolic function improved with an EF of 55% on TTE. A cardiac MRI was performed which did not show any delayed enhancement (Figs 1B & 1C) and EF was noted to be 66%. Discussion Local anesthetics like bupivacaine have been widely used for peripheral nerve blocks and trigger point injections. Cardiotoxicity secondary to Bupivacaine has been reported after an overdose or accidental intravascular or intrathecal injection. Depression of myocardial conduction and contractility by blocking cardiac sodium channels is thought to be the mechanism. Acute left ventricular dysfunction mimicking acute coronary syndrome (ACS) after local bupivacaine injection is very rare. Interestingly the onset was hyper-acute and recovery was very quick with GDMT, the mechanism of which is not well understood. In conclusion, acute heart failure as a potential acute complication should be on the radar for the physicians administering regional bupivacaine. This diagnosis of exclusion can mimic ACS and has a very good prognosis.

cardiac & cardiovascular systems